Treatment and Long-Term Safety Outcomes of Peptide Receptor Radionuclide Therapy for Metastatic Neuroendocrine Tumours: An Asian Experience.

MLA

Tham, Wei Ying, et al. “Treatment and Long-Term Safety Outcomes of Peptide Receptor Radionuclide Therapy for Metastatic Neuroendocrine Tumours: An Asian Experience.” Neuroendocrinology, vol. 114, no. 9, Sept. 2024, pp. 840–47. EBSCOhost, https://doi.org/10.1159/000538523.

APA

Tham, W. Y., Huang, H. L., Tai, D. W. M., Allen Jr., J. C., Hwang, J. S. G., Loh, L. M., Goh, B. K. P., Ong, S. Y. K., Kek, P. C., Tan, D. M. Y., Ng, D. C. E., & Loke, K. S. H. (2024). Treatment and Long-Term Safety Outcomes of Peptide Receptor Radionuclide Therapy for Metastatic Neuroendocrine Tumours: An Asian Experience. Neuroendocrinology, 114(9), 840–847. https://doi.org/10.1159/000538523

Chicago

Tham, Wei Ying, Hian Liang Huang, David Wai Meng Tai, John C. Allen Jr., Jacqueline S.G. Hwang, Lih Ming Loh, Brian K.P. Goh, et al. 2024. “Treatment and Long-Term Safety Outcomes of Peptide Receptor Radionuclide Therapy for Metastatic Neuroendocrine Tumours: An Asian Experience.” Neuroendocrinology 114 (9): 840–47. doi:10.1159/000538523.